The FDA IND approval marks a pivotal step for the company's lead compound, known as Lucid-MS. What sets Quantum BioPharma’s…
Cancer care has evolved over the past decades and one would expect that the more the field evolves, the easier…
In the United States alone, close to one million people are living with MS, with a landmark study finding that…
A nationwide survey conducted by the Commonwealth Fund has found that contrary to a common view that it is the…
Earth Science Tech has uplisted to the OTCQB Venture Market, a premier public market that provides investors with a trusted…
VERAXA is advancing an oncology pipeline centered on its proprietary BiTAC(R) platform, alongside additional antibody-drug conjugate and engineered-antibody technologies. The…
A new study has found that the risk of people developing sepsis, meningitis or pneumonia as a result of exposure…
Scientists have been struggling to understand why more people who are less than 55 years of age are being diagnosed…
For decades, lots of American patients have been traveling to “fringe” countries like Turkey, Cuba and Thailand in search of…
VERAXA is developing antibody-based cancer therapies aimed at improving the therapeutic window of existing treatment modalities. Its proprietary BiTAC platform…